Literature DB >> 832537

Activity of fosfomycin in the treatment of bacterial infections.

R Hutzler, V Fernandes, D Muñoz, A Rozentraub.   

Abstract

30 patients with different infections were treated with fosfomycin: 13 had urinary infections, 14 had pneumonial infections, 2 had staphylococcus osteomyelitis and 1 had staphylococcus septicemia. The antibiotic was administered in doses ranging from 100 to 230 mg/kg/day, with periods of treatment that lasted from 5 to 58 days. The doses were administered every 6 h by the oral or intramuscular route. A total of 35 organisms were isolated: 7 E. coli, 7beta-hemolitic Streptococcus, 6 Proteus sp., 6 S. aureus, 6 S. viridans, 2 Klebsiella sp. and 1 negative coagulase S. aureus. All were sensitive to fosfomycin in vitro, as was revealed by the diffusion in discs method. The therapeutic results were good in 29 of the 30 cases (96.7%). There were no important side effects. A patient complained of a local pain in the area of the injection. The transaminases increased temporarily in 2 patients. One patient had a moderate eosinophilia while under treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832537     DOI: 10.1159/000222076

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia.

Authors:  W Y Lau; C H Teoh-Chan; S T Fan; K F Lau
Journal:  J Hyg (Lond)       Date:  1986-06

2.  In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Authors:  Dmitri Iarikov; Ronald Wassel; John Farley; Sumathi Nambiar
Journal:  Infect Dis Ther       Date:  2015-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.